Evidence map›Paper›PMID 41269449›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026

Recovery of nontuberculous mycobacteria from non-cystic fibrosis respiratory specimens using a decontamination-free selective agar.

Tina I Bui, Jodie R Dolan, Carol E Muenks, Sylvain Orenga, Melanie L Yarbrough, Allison R Eberly

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tina I BuiDepartment of Pathology and Immunology, Washington University School of Medicine, 660 S Euclid Ave., St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-4110-3263
Jodie R DolanDepartment of Pathology and Immunology, Washington University School of Medicine, 660 S Euclid Ave., St. Louis, MO, USA.
Carol E MuenksDepartment of Pathology and Immunology, Washington University School of Medicine, 660 S Euclid Ave., St. Louis, MO, USA.ORCID http://orcid.org/0000-0003-4294-8134
Sylvain OrengaMicrobiology Research & Development, bioMérieux, 3 route de Port Michaud, La Balme-les-Grottes, 38 390, France.
Melanie L YarbroughDepartment of Pathology and Immunology, Washington University School of Medicine, 660 S Euclid Ave., St. Louis, MO, USA.ORCID http://orcid.org/0000-0003-2166-7552
Allison R EberlyDepartment of Pathology and Immunology, Washington University School of Medicine, 660 S Euclid Ave., St. Louis, MO, USA. a.eberly@wustl.edu.ORCID http://orcid.org/0000-0002-1094-8407

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Digestion and decontamination during acid-fast bacilli (AFB) culture processing are performed to suppress growth of normal microbiota in respiratory specimens; however, these steps may render AFB nonviable. This study aimed to evaluate the performance of NTM Elite agar, a decontamination-free selective medium, for the recovery of nontuberculous mycobacteria (NTM) compared to standard of care (SOC) processing and solid and liquid media inoculation for AFB culture in five hundred lower respiratory samples from non-cystic fibrosis patients. Concurrently, the same specimens were directly inoculated onto NTM Elite agar (NTM Elite-Direct Inoculation) or centrifuged and washed with saline prior to inoculation onto NTM Elite agar (NTM Elite-Concentrated) and incubated up to 28 days. The overall median time to positivity was 7.0 days (IQR = 7-18) for NTM Elite-Direct Inoculation and 14 days (IQR = 7-14) for NTM Elite-Concentrated, which were similar to SOC broth but shorter than SOC solid agar at 35 days (IQR = 2-41). Breakthrough non-AFB growth rate was 1.4% (7/500) NTM Elite-Direct Inoculation, which was less than NTM Elite-Concentrated at 9.0% (45/500) and SOC media at 10.0% (50/500). Forty-five unique isolates were included in the analysis for sensitivity of NTM detection. Sensitivity was 43.5% (95% CI = 30.2-57.8) for SOC media, 20.0% (95% CI = 10.9-33.8) for NTM Elite-Direct Inoculation, and 82.6% (95% CI = 69.3-90.9) for NTM Elite-Concentrated. Combined with SOC broth culture, sensitivity was 93.3% (95% CI = 82.1-97.7) for NTM Elite-Concentrated. The high sensitivity of the latter procedure indicates potential for NTM Elite agar to replace SOC solid agar for detection of NTM in areas of high NTM incidence but low incidence of tuberculosis.

Indexed as

Bacteriological TechniquesCulture MediaMycobacterium Infections, NontuberculousNontuberculous MycobacteriaAdultAgarDecontaminationFemaleHumansMaleMiddle AgedSpecimen HandlingSputumAgarCulture MediaAcid-fast bacilliMycobacteriaNontuberculous mycobacteriaNTM Elite agar

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.